Massive Bio has announced a collaboration with OpenAI to enhance global access to clinical trials through artificial intelligence-enabled parameterization and real-time patient pre-screening. The initiative is part of OpenAI’s Impact Hours program, which supports projects designed to deliver large-scale societal benefits.
Through this collaboration, Massive Bio has developed capabilities to convert complex clinical trial eligibility criteria—from both sponsors and public registries such as ClinicalTrials.gov—into structured, machine-readable parameters. This transformation enables automated and immediate patient pre-screening against active trials, significantly reducing the time required to identify suitable matches and lowering operational burden.
The resulting infrastructure introduces a scalable, AI-driven system for patient-trial matching across oncology and hematology. By replacing manual interpretation of trial requirements with AI-based parameterization, the platform supports faster identification of eligible patients, improved referral processes, and broader global reach.
Arturo Loaiza-Bonilla, MD, MSEd, FACP, Chief Medical AI Officer at Massive Bio, said, "Clinical trials have historically been limited by accessibility and operational complexity. By collaborating with OpenAI, we are transforming how trials are interpreted and operationalized, making pre-screening faster, more scalable, and significantly more accessible to patients worldwide. This collaboration enables us to move from static, manually curated eligibility criteria toward a dynamic, AI-driven parameterization layer that continuously aligns patients with the right trials in real time. It is exactly the kind of infrastructure-level deployment that can close the gap between the thousands of open trials and the millions of patients who never learn they may qualify."
The collaboration aligns with broader developments in clinical AI tools, including OpenAI’s launch of ChatGPT for Clinicians, which is designed to support healthcare professionals with clinical workflows, research, and decision-making tools.
Selin Kurnaz, PhD, Co-Founder and CEO of Massive Bio, emphasized the shared vision, stating, "OpenAI's commitment to making AI directly useful for clinicians through ChatGPT for Clinicians validates the same vision we have been building toward across our platforms. We are leveraging the same advantages, scalable AI infrastructure, real-time clinical intelligence, and physician-centered design, throughout PatientConnect, TrialRelay, and across our Reticulum Nexus multiagentic AI system. When clinicians can use AI to streamline their workflows and when patients can be pre-screened against clinical trials in seconds rather than weeks, we are collectively removing the barriers that have kept clinical trial enrollment rates unacceptably low for decades."
Anna Makanju, VP of Global Impact at OpenAI, added, "Expanding access to clinical trials is a fantastic demonstration of how AI can improve health outcomes at scale. Our collaboration with Massive Bio helps ensure that these opportunities are available to patients in every region, not just those with proximity to major research centers."
As part of the initiative, Massive Bio is also offering free pre-screening services in selected regions, aiming to reduce access barriers and improve equity in clinical trial participation.
Click here for the original news story.
